Suman Kambhampati, MD

A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.

Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.

Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.